The combination of recombinant factor VIIa and fibrinogen correct clotting ex vivo in patient samples obtained following cardiopulmonary bypass surgery

Thrombosis Research

Volumn 124, Issue 6, 2009, Pages 695-700

  Sørensen, Benny ^b,c   Asvaldsdottir, Hanna S ^a   Gudmundsdottir, Brynja R ^a   Onundarson, Pall T ^a  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiac surgery; Coagulopathy; Fibrinogen; Platelet function; Recombinant factor VIIa; Thromboelastometry

Indexed keywords

ACETYLSALICYLIC ACID; ANTIPLASMIN; ANTITHROMBIN; D DIMER; ENOXAPARIN; FIBRINOGEN; HEMOGLOBIN; HEPARIN; HEPARIN LYASE; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; PROTEIN C; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT THROMBOPLASTIN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; ERYTHROCYTE COUNT; EX VIVO STUDY; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; LEUKOCYTE COUNT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURGICAL PATIENT; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; CARDIOPULMONARY BYPASS; FACTOR VIIA; FIBRINOGEN; HEPARIN; HEPARIN LYASE; HUMANS; MIDDLE AGED; PROTAMINES; RECOMBINANT PROTEINS;

EID: 70449716975     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.08.008     Document Type: Article

References (36)

1. Linden M.D. The hemostatic defect of cardiopulmonary bypass. J Thromb Thrombolysis 16 (2003) 129-147
2. Hartmann M., Sucker C., Boehm O., Koch A., Loer S., and Zacharowski K. Effects of cardiac surgery on hemostasis. Transfus Med Rev 20 (2006) 230-241
3. Despotis G.J., Avidan M.S., and Hogue Jr. C.W. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72 (2001) S1821-S1831
4. Karthik S., Grayson A.D., McCarron E.E., Pullan D.M., and Desmond M.J. Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay. Ann Thorac Surg 78 (2004) 527-534
5. Dacey L.J., Munoz J.J., Baribeau Y.R., Johnson E.R., Lahey S.J., Leavitt B.J., et al. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 133 (1998) 442-447
6. Ferraris V.A., Ferraris S.P., Saha S.P., Hessel E.A., Haan C.K., Royston B.D., et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 83 (2007) S27-S86
7. Al Douri M., Shafi T., Al Khudairi D., Al Bokhari E., Black L., Akinwale N., et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 11 Suppl 1 (2000) S121-S127
8. Brandsborg S., Sørensen B., Poulsen L.H., and Ingerslev J. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients. Blood Coagul Fibrinolysis 17 (2006) 241-249
9. Karkouti K., Beattie W.S., Wijeysundera D.N., Yau T.M., McCluskey S.A., Ghannam M., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45 (2005) 26-34
10. Rossaint R., Duranteau J., Stahel P.F., and Spahn D.R. Nonsurgical treatment of major bleeding. Anesthesiol Clin 25 (2007) 35-48 viii
11. Fenger-Eriksen C., Anker-Moller E., Heslop J., Ingerslev J., and Sørensen B. Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 94 (2005) 324-329
12. Sørensen B., and Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 11 Suppl 1 (2005) 1-6
13. Sørensen B., and Ingerslev J. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 96 (2006) 446-453
14. Sørensen B., and Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2 (2004) 102-110
15. Sørensen B., Persson E., and Ingerslev J. Factor VIIa analogue (V158D/E296 V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 137 (2007) 158-165
16. Larsen O.H., Clausen N., Persson E., Ezban M., Ingerslev J., and Sorensen B. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue. Br J Haematol 144 1 (2008) 99-106
17. Ingerslev J., Poulsen L.H., and Sørensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 9 (2003) 348-352
18. Hvas A.M., Sorensen H.T., Norengaard L., Christiansen K., Ingerslev J., and Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 5 (2007) 2408-2414
19. Tanaka K.A., Taketomi T., Szlam F., Calatzis A., and Levy J.H. Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg 106 (2008) 732-738 table
20. Sørensen B., Johansen P., Christiansen K., Wöelke M., and Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1 (2003) 551-558
21. Lang T., Johanning K., Metzler H., Piepenbrock S., Solomon C., Rahe-Meyer N., et al. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg 108 (2009) 751-758
22. Lauritzen B., Hedner U., Johansen P.B., Tranholm M., and Ezban M. Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats. J Thromb Haemost 6 (2008) 804-811
23. Ganter M.T., Schmuck S., Hamiel C.R., Wischmeyer P.E., Heule D., Zollinger A., et al. Monitoring recombinant factor VIIa treatment: efficacy depends on high levels of fibrinogen in a model of severe dilutional coagulopathy. J Cardiothorac Vasc Anesth 22 (2008) 675-680
24. Fenger-Eriksen C., Tonnesen E., Ingerslev J., and Sorensen B. Recombinant factor VIIa and fibrinogen display additive effect during in vitro haemodilution with crystalloids. Acta Anaesthesiol Scand 53 (2009) 332-338
25. Karlsson M., Ternstrom L., Hyllner M., Baghaei F., Nilsson S., and Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 48 (2008) 2152-2158
26. Nielsen V.G., and Levy J.H. Fibrinogen and bleeding: old molecule-new ideas. Anesth Analg 105 (2007) 902-903
27. Fenger-Eriksen C., Jensen T.M., Kristensen B.S., Jensen K.M., Tonnesen E., Ingerslev J., et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 7 (2009) 795-802
28. Butenas S., Brummel K.E., Bouchard B.A., and Mann K.G. How factor VIIa works in hemophilia. J Thromb Haemost 1 (2003) 1158-1160
29. Hoffman M., and Monroe III D.M. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 38 (2001) 6-9
30. Persson E., Kjalke M., and Olsen O.H. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A 98 (2001) 13583-13588
31. Fries D., Krismer A., Klingler A., Streif W., Klima G., Wenzel V., et al. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth 95 (2005) 172-177
32. Wolberg A.S. Thrombin generation and fibrin clot structure. Blood Rev 21 (2007) 131-142
33. Wiinberg B., Jensen A.L., Rozanski E., Johansson P.I., Kjelgaard-Hansen M., Tranholm M., et al. Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs. Vet J 179 1 (2007) 121-129
34. Sedrakyan A., Treasure T., and Elefteriades J.A. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 128 (2004) 442-448
35. Podda G.M., Bucciarelli P., Lussana F., Lecchi A., and Cattaneo M. Usefulness of PFA-100 testing in the diagnostic screening of patients with suspected abnormalities of hemostasis: comparison with the bleeding time. J Thromb Haemost 5 (2007) 2393-2398
36. Vincentelli A., Susen S., Le T.T., Six I., Fabre O., Juthier F., et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 349 (2003) 343-349